FDA Clears Dupixent for Chronic Hives After Decade Without New Options
FDA greenlights dupilumab for chronic spontaneous urticaria in patients 12 and older with symptoms unresponsive to antihistamines
Topline
Dupilumab (Dupixent) has received FDA approval as an add-on treatment for chronic spontaneous urticaria (CSU) in patients aged 12 and older who continue to experience symptoms despite using H1 antihistamines.
Study Details
Chronic spontaneous urticaria (CSU) is a distressing inflammatory skin condition marked by recurring, unpredictable hives and i…
